Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.BREAST.2011.02.015 | ||||
| Año | 2011 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
In middle resource countries (MRCs), cancer control programs are becoming a priority as the pattern of disease shifts from infectious diseases to non-communicable diseases such as breast cancer, the most common cancer among women in MRCs. The Middle Resource Scenarios Working Group of the BHGI 2010 Global Summit met to identify common issues and obstacles to breast cancer detection, diagnosis and treatment in MRCs. They concluded that breast cancer early detection programs continue to be important, should include clinical breast examination (CBE) with or without mammography, and should be coupled with active awareness programs. Mammographic screening is usually opportunistic and early detection programs are often hampered by logistical and financial problems, as well as socio-cultural barriers, despite improved public educational efforts. Although multidisciplinary services for treatment are available, geographical and economic limitations to these services can lead to an inequity in health care access. Without adequate health insurance coverage, limited personal finances can be a significant barrier to care for many patients. Despite the improved availability of services (surgery, pathology, radiology and radiotherapy), quality assurance programs remain a challenge. Better access to anticancer drugs is needed to improve outcomes, as are rehabilitation programs for survivors. Focused and sustained government health care financing in MRCs is needed to improve early detection and treatment of breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Yip, Cheng-Har | - |
Univ Malaya - Malasia
University of Malaya Medical Centre - Malasia |
| 2 | Cazap, Eduardo | Hombre |
SLACOM Soc Latinoamer & Caribe Oncol Med - Argentina
SLACOM-Sociedad Latinoamericana y del Caribe de Oncología Médica - Argentina |
| 3 | Anderson, Benjamin O. | Hombre |
UNIV WASHINGTON - Estados Unidos
University of Washington, Seattle - Estados Unidos Fred Hutchinson Cancer Research Center - Estados Unidos University of Washington - Estados Unidos |
| 4 | Bright, Kristin L. | Mujer |
NYU - Estados Unidos
NYU Grossman School of Medicine - Estados Unidos |
| 5 | Caleffi, Maira | Mujer |
Hosp Moinhos Venta - Brasil
Hospital Moinhos de Vento - Brasil |
| 6 | Cardoso, Fatima | Mujer |
European Sch Oncol - Italia
Champalimaud Canc Ctr - Portugal European School of Oncology - Italia Champalimaud Cancer Center - Portugal |
| 7 | Elzawawy, Ahmed M. | Hombre |
ICEDOC - Egipto
International Campaign for Establishment and Development of Oncology Centers (ICEDOC) - Egipto |
| 8 | Harford, Joe B. | Hombre |
NCI - Estados Unidos
National Cancer Institute - Estados Unidos National Cancer Institute (NCI) - Estados Unidos |
| 9 | Krygier, Gabriel D. | Hombre |
Acad Univ Clin Hosp Montevideo - Uruguay
Natl Breast Canc Program - Uruguay Hospital de Clínicas Dr. Manuel Quíntela - Uruguay National Breast Cancer Program - Uruguay |
| 10 | Masood, Shahla | Mujer |
UNIV FLORIDA - Estados Unidos
University of Florida College of Medicine - Estados Unidos |
| 11 | Murillo, Raul | Hombre |
Inst Nacl Cancerol Colombia - Colombia
Instituto Nacional de Cancerología de Colombia - Canadá |
| 12 | Muse, Ignacio M. | Hombre |
Natl Canc Program - Uruguay
National Breast Cancer Program - Uruguay Natl Breast Canc Program - Uruguay |
| 13 | Otero, Isabel V. | Mujer |
NCI - Estados Unidos
National Cancer Institute - Estados Unidos National Cancer Institute (NCI) - Estados Unidos |
| 14 | Passman, Leigh J. | Mujer |
Instituto Nacional del Cancer - Brasil
Instituto Nacional de Câncer - Brasil National Cancer Institute - Estados Unidos National Cancer Institute (NCI) - Brasil |
| 15 | SANTINI-RODRIGUES, LUIZ ANTONIO | - |
Instituto Nacional del Cancer - Brasil
Instituto Nacional de Câncer - Brasil National Cancer Institute - Estados Unidos National Cancer Institute (NCI) - Brasil |
| 16 | Ferreira da Silva, Ronaldo Correa | Hombre |
Instituto Nacional del Cancer - Brasil
Shanghai Municipal Ctr Dis Control & Prevent - China Instituto Nacional de Câncer - Brasil Shanghai Municipal Center for Disease Control and Prevention - China |
| 16 | da Silva, Ronaldo Corrêa Ferreira | Hombre |
Instituto Nacional de Câncer - Brasil
Shanghai Municipal Center for Disease Control and Prevention - China National Cancer Institute - Estados Unidos National Cancer Institute (NCI) - Brasil |
| 17 | Thomas, David B. | Hombre |
Fred Hutchinson Cancer Research Center - Estados Unidos
|
| 18 | TORRES-DIAZ, MARIA SOLEDAD | Mujer |
Clínica Las Condes - Chile
|
| 19 | Zhengs, Ying | - |
Shanghai Municipal Ctr Dis Control & Prevent - China
Shanghai Municipal Center for Disease Control and Prevention - China |
| 20 | Khaled, Hussein M. | Hombre |
Cairo Univ - Egipto
Cairo University - Egipto |
| Fuente |
|---|
| National Institutes of Health |
| GlaxoSmithKline |
| National Cancer Institute |
| U.S. Department of Health and Human Services |
| GSK |
| European School of Oncology |
| Sanofi-Aventis |
| U.S. Department of Defense |
| Pan American Health Organization |
| Breast Cancer Research Foundation |
| Centers for Disease Control and Prevention |
| GlaxoSmithKline Australia |
| GE Healthcare |
| UICC |
| Susan G. Komen for the Cure |
| Office of Research on Women’s Health |
| Bayer Sherling Pharma |
| Breast Cancer Research Foundation (BCRF) |
| Breast Health Global Initiative (BHGI) |
| Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer |
| U.S. Office of Science Planning and Assessment, National Cancer Institute |
| U.S. Office of Research on Women's Health, National Institutes of Health |
| U.S. Office of Women's Health, Department of Health and Human Services |
| U.S. Centers for Disease Control and Prevention |
| American Society of Clinical Oncology |
| Fred Hutchinson Cancer Research Center |
| Susan G. Komen for the CureRegistered |
| LIVESTRONG |
| ASCO |
| U.S. Office of International Affairs, National Cancer Institute |
| ESMO |
| U.S. Office of International Affairs |
| U.S. Department of Defense Breast Cancer Research Program Center of Excellence |
| International Union Against Cancer |
| European Society for Medical Oncology |
| Office of Science Planning and Assessment |
| Connecticut Breast Health Initiative |
| Office of Women’s Health |
| Office of Research on Women's Health |
| Office of International Affairs |
| Breast Health Global Initiative |
| Office of Women's Health |
| GE Healthcare and Sanofi-Aventis |
| Agradecimiento |
|---|
| BHGI received (2010 Global Summit) grants and contributions from Fred Hutchinson Cancer Research Center; Susan G. Komen for the Cure (R) (Grant Award SG09-0605-01-BHGI); U.S. Office of International Affairs, National Cancer Institute; European School of Oncology; Pan American Health Organization; Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer; American Society of Clinical Oncology; LIVESTRONG; U.S. Centers for Disease Control and Prevention; U.S. Office of Women's Health, Department of Health and Human Services; U.S. Office of Science Planning and Assessment, National Cancer Institute; U.S. Office of Research on Women's Health, National Institutes of Health and unrestricted educational grants from GE Healthcare and Sanofi-Aventis. |
| BOA received funding from Breast Health Global Initiative (BHGI) , EC received consultancy funding from Bayer Sherling Pharma, grants from Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals, was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and received travel expenses from ASCO, UICC, ESMO, and BCRF; CHY was on an expert panel and received research funding from GSK and was on the speakers bureaus for Sanofi-Aventis and Roche. DBT has received funding from BHGI for travel. KB received funding from U.S. Department of Defense Breast Cancer Research Program Center of Excellence ( #W81XWH-04-1-0905 ). All other authors and working group members reported no conflict of interest. |